New drug shows promise in slowing ALS progression?
NCT ID NCT00415519
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This study tested a drug called MCI-186 in 25 people with advanced ALS (severity grade III). The goal was to see if daily intravenous doses could slow the decline in daily function over 24 weeks compared to a placebo. The trial was exploratory, meaning it looked for signals of effectiveness and safety rather than proving a definitive benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.